Bedrijfsoverzicht
KALA BIO, Inc. is a clinical-stage biopharmaceutical entity focused on the research, development, and commercialization of specialized therapies designed to address rare and severe eye diseases. The company operates within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high capital requirements for drug discovery and regulatory approval processes before products reach the market. As of the latest available data, the company possesses a market capitalization of $185.00M and maintains an operational workforce of 38 employees. The combination of a market cap of $185.00M with an annual revenue figure listed as N/A indicates that the company is a pre-revenue or early-stage development entity where valuation is driven primarily by intellectual property and pipeline potential rather than current sales performance.
Financiële gezondheid
The company reports a Net Income (TTM) of $-35,841,000 and an EBITDA of $-41,311,000, while Revenue (TTM) is listed as N/A. The significant negative gap between the N/A revenue figure and the substantial net loss of $-35,841,000 reveals a cost structure dominated by research and development expenditures typical of clinical-stage firms, where operating expenses far exceed current income generation capabilities. The Free Cash Flow stands at $-22,026,250, indicating that the company is burning cash at a rate of over $22 million annually, which suggests limited financial flexibility until successful commercialization or significant capital raising events occur. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated sufficient revenue to calculate meaningful percentage margins or has incurred costs that result in zero profitability on sales. On the balance sheet, the company holds $21.10M in cash against $29.94M in debt, resulting in a negative liquidity position, while the Debt to Equity ratio is listed as N/A due to the lack of reported equity or the specific calculation method used in the data source. The Current Ratio is 0.74, which indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity challenges that must be managed through cash reserves or financing. Furthermore, the Return on Equity is N/A and the Return on Assets is -65.8%, metrics that collectively reveal that management is currently utilizing the company's asset base to generate significant negative returns, a common characteristic of early-stage biotechnology firms prior to product approval.
Waarderingsbeoordeling
The Trailing P/E Ratio (TTM) is listed as N/A and the Forward P/E is -0.03, a disparity that implies the company has not yet achieved positive earnings required for traditional multiple-based valuation and that forward projections currently reflect negative earnings expectations. The Price to Book ratio is -0.17, indicating a negative book value relative to the market price, which suggests the market is pricing the company based on future potential rather than tangible asset backing. The Price to Sales ratio is N/A and the EV/EBITDA is -0.25, alternative valuation metrics that suggest the company cannot be valued using standard revenue or earnings multiples due to its lack of positive profitability and revenue history. The stock's 52-Week High is $20.60 and the 52-Week Low is $0.15, placing the current trading price in a highly volatile range where the stock has experienced extreme fluctuations relative to its historical trading band. The Beta value is -1.99, a negative figure that implies the stock's price volatility moves in the opposite direction of the broader market and exhibits amplified sensitivity to market movements, creating a unique risk profile distinct from standard equities.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated from prior year data. Since the company is a non-dividend payer, it does not distribute a Dividend Yield, which is N/A, nor does it have a Payout Ratio, recorded as 0.0%, as all available financial resources are theoretically directed toward sustaining operations and advancing clinical trials rather than shareholder distributions. This reinvestment strategy is standard for biotechnology companies in the development phase, where capital is prioritized for research and development to achieve product milestones. Overall, the growth and income profile is defined by a complete absence of current financial growth metrics and dividend income, relying entirely on the potential value unlock from future clinical trial successes and regulatory approvals.